HR+/HER2- BREAST CANCER: TRANSFORMING ONCOLOGY WITH NEW TREATMENTS

Epidemiology of HR+/HER2- Breast Cancer HR+ HER2- breast cancer is the most prevalent subtype, accounting for approximately 70% of all breast cancer cases. Defined by hormone receptor positivity and the absence of HER2 overexpression, its prevalence varies across different regions, with higher incidence rates observed in developed countries due to